Evaluate expects Roche to lead the way in steady pharma growth to 2028

Intelligence company Evaluate predicts sales in the global pharmaceutical industry to grow by 6% per year between 2022 and 2028, according to its annual World Preview report.

The report forecasts that industry revenues will hit $1.6 trillion in six years’ time and anticipates that leading this market will be Roche (ROG: SIX). The Swiss pharma giant’s sales are predicted to be $62.7 billion in 2028, accounting for 3.9% of the worldwide market.

US drugmaker AbbVie (NYSE: ABBV) is seen as a close second with prescription sales of $62 billion that year. The fastest growing big pharma player will be Anglo-Swedish firm AstraZeneca (LSE: AZN), according to Evaluate, with a top-line predicted to expand by 5.8% year on year, to 2028.